Efeitos farmacológicos da suplementação dietética com arginina em ratos com tumor sólido de Walker 256

Os efeitos da suplementação com arginina na dieta de portadores de câncer são controversos. O objetivo deste trabalho é avaliar os efeitos da suplementação dietética com arginina no cresciemnto tumoral, disserninação metastática, metabolismo de aminoácidos, alterações hematológicas, tempo de sobrevida e peso corporal de ratos Wistar com tumor sólido de Walker 256. Foram administradas soluções por via gástrica, contendo arginina nas concentrações de 4%, 6% e dieta padrão (controle). A suplementação com arginina inibiu a disseminação de células tumorais no modelo experimental, embora o crescimento tumoral não tenha sido afetado significantemente. O tempo de sobrevida dos animais com tumor sólido não foi afetado de forma significativa. Foi observado diminuição significativa do peso corpóreo após a administração da arginina a 6% (pPharmacological effects of arginine supplementation in rats with Walker 256 solid tumor. The effects of diet arginine supplementation for those with cancer are controversial. We evaluate the effects of dietetic supplementation with arginine over body weight, growth of tumor, metastatic dissemination, surviving time, amino acid metabolism, haematological changes of the rats with Walker 256 solid tumor. Intragastrical solutions with arginine at 4% and 6%, a standard diet (control) were administered to the animals. The supplementation with arginine was associated with a lower weight gain during the study period (p<0.05). Surviving time of the rats with solid tumor did not vary significantly between the groups. The rate of metastase was lower in animals with Walker 256 solid tumor supplemented with arginine. The amino acid metabolism was estimulate in the animals after arginin supplementation at 4% and 6%, demonstrated by significant increases in blood levels of arginine, ornitine, citruline, proline and histidin when compared to the control group. Anaemia was less severe in the rats with Walker 256 solid tumor that received arginine supplementation. The results suggest that arginine 6% supplementation may have pharmacologic effect in rats with Walker 256 solid beyon the nutritional one

Efeitos farmacológicos da suplementação dietética com arginina em ratos com tumor sólido de Walker 256

Os efeitos da suplementação com arginina na dieta de portadores de câncer são controversos. O objetivo deste trabalho é avaliar os efeitos da suplementação dietética com arginina no cresciemnto tumoral, disserninação metastática, metabolismo de aminoácidos, alterações hematológicas, tempo de sobrevida e peso corporal de ratos Wistar com tumor sólido de Walker 256. Foram administradas soluções por via gástrica, contendo arginina nas concentrações de 4%, 6% e dieta padrão (controle). A suplementação com arginina inibiu a disseminação de células tumorais no modelo experimental, embora o crescimento tumoral não tenha sido afetado significantemente. O tempo de sobrevida dos animais com tumor sólido não foi afetado de forma significativa. Foi observado diminuição significativa do peso corpóreo após a administração da arginina a 6% (p<0.05). O metabolismo dos aminoácidos foi estimulado após ingestão de suplementos com arginina, evidenciado pelos aumentos significativos dos níveis sanguíneos de arginina, ornitina, citrulina, prolina e histidina quando comparados ao grupo controle (p<0.001). O grau de anemia no tumor sólido foi menos severo nos grupos que receberam suplementação com arginina, evidenciado através do hemograma (p<0.001) e da análise citológica. Os resultados sugerem que a suplementação dietética com arginina a 6% apresentou algum efeito benéfico no tumor sólido de Walker 256 que ultrapassa o efeito nutricional

Tabapuã breed in Northeastern Brazil: genetic progress and population structure

The objective of this study was to evaluate the history of the Tabapuã breed in Northeastern Brazil by determining its population structure and genetic progress. Pedigree information from animals born in the period between 1965 and 2006 and weight-adjusted data at 205 (W205), 365 (W365) and 550 (W550) days of age for bovines born between 1975 and 2006 were used. The (co)variance components and genetic value were estimated using the application MTDFREML. Also, the software ENDOG was used for pedigree analysis and parameter estimation based on the probabilities of gene origin, inbreeding and average generation interval. The heritability coefficients for direct genetic effects were 0.21±0.03, 0.26±0.04 and 0.36±0.05 for W205, W365 and W550, respectively. During the first 20 years studied, the observed effective size was small. The generation intervals by gametic pathway were: 7.7±3.4 (sire-son), 7.8±3.7 (sire-daughter), 6.9±3.3 (dam-son), 6.8 ± 3.1 (dam-daughter), and mean interval of 7.3±3.4 years. The studied population showed moderate heritability coefficients, whereas the genetic gains based on the studied traits may be higher than those estimated by genetic tendencies. Reduced generation interval, increased effective size and continuous mating control of relatives are important strategies for the genetic progress of the Tabapuã breed in the region

30-day morbidity and mortality of sleeve gastrectomy, Roux-en-Y gastric bypass and one anastomosis gastric bypass: a propensity score-matched analysis of the GENEVA data

Background: There is a paucity of data comparing 30-day morbidity and mortality of sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and one anastomosis gastric bypass (OAGB). This study aimed to compare the 30-day safety of SG, RYGB, and OAGB in propensity score-matched cohorts. Materials and methods: This analysis utilised data collected from the GENEVA study which was a multicentre observational cohort study of bariatric and metabolic surgery (BMS) in 185 centres across 42 countries between 01/05/2022 and 31/10/2020 during the Coronavirus Disease-2019 (COVID-19) pandemic. 30-day complications were categorised according to the Clavien–Dindo classification. Patients receiving SG, RYGB, or OAGB were propensity-matched according to baseline characteristics and 30-day complications were compared between groups. Results: In total, 6770 patients (SG 3983; OAGB 702; RYGB 2085) were included in this analysis. Prior to matching, RYGB was associated with highest 30-day complication rate (SG 5.8%; OAGB 7.5%; RYGB 8.0% (p = 0.006)). On multivariate regression modelling, Insulin-dependent type 2 diabetes mellitus and hypercholesterolaemia were associated with increased 30-day complications. Being a non-smoker was associated with reduced complication rates. When compared to SG as a reference category, RYGB, but not OAGB, was associated with an increased rate of 30-day complications. A total of 702 pairs of SG and OAGB were propensity score-matched. The complication rate in the SG group was 7.3% (n = 51) as compared to 7.5% (n = 53) in the OAGB group (p = 0.68). Similarly, 2085 pairs of SG and RYGB were propensity score-matched. The complication rate in the SG group was 6.1% (n = 127) as compared to 7.9% (n = 166) in the RYGB group (p = 0.09). And, 702 pairs of OAGB and RYGB were matched. The complication rate in both groups was the same at 7.5 % (n = 53; p = 0.07). Conclusions: This global study found no significant difference in the 30-day morbidity and mortality of SG, RYGB, and OAGB in propensity score-matched cohorts. © 2021, The Author(s)